TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07439094: A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Sponsor: Chong Kun Dang Pharmaceutical · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07439094 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07439094 Rescue Dossier →